Searched for
KV PHARMACEUTICALS
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...- Holding stocks is harder than finding them: 10 mid- and small-caps stocks that may be worth holding on toHolding a stock is not an act of blind faith. It is not refusing to change one’s mind. It is not averaging down because the stock has falle...
- Mentha oil may touch Rs 2,000/kgOn MCX on Tuesday, contracts for December delivery jumped by 1 per cent to Rs 1,724/kg.
- Fourteen stocks in focus on Tuesday, 20 December 2016Goldman Sachs initiated coverage on Coal India with ‘Buy’ rating with a target price of Rs 360.
- Sensex rangebound; top fifteen stocks in focusThe Nifty was at 7,728.70, up 13.90 points or 0.18 per cent. It touched intraday high of 7,731.45 and a low of 7,708.90 in trade today.
- Fifteen stocks in focus in Friday morning tradeIndian markets are expected to trade in a range. Here is a list of fifteen stocks which are likely to be in focus today.
- Infosys independent director Ann M Fudge not to seek re-appointment after her term expires on June 14Ann M Fudge also serves on a number of other corporate boards, including GE, Novartis International and retail behemoth Unilever.
- Zydus Cadila buys out Biochem PharmaceuticalsZydus Cadila has acquired 100% stake in Mumbai-based Biochem Pharmaceuticals for an undisclosed amount.
- Zydus Cadila in talks to acquire brands and manufacturing facility of Biochem PharmaceuticalsThe deal is expected to be valued at Rs 300-450 cr and will boost Biochem's revenue growth. In fiscal 2009-10, Biochem reported revenues of...
- Zydus plans to buy US drug cos for $60 mnZydus Cadila plans to acquire US-based generic pharma company. The Ahmedabad-based firm signed an asset purchase agreement with a US-based ...
- Sequoia Cap invests Rs 70 cr in Celon LabsPrivate equity major Sequoia Capital has made its first investment in the pharmaceutical sector in the country by pumping in `70 crore into...
- Rel Life Sciences to focus on R&D, for nowThe company is all set to launch fifth biosimilar drug and seeks approvals for clinical trials and stem-cell treatment.
- Reliance Life plans to launch biosimilar drug in EuropeMukesh Ambani-owned Reliance Life Sciences to launch biosimilar drug in Europe within a year since it has completed all required testing an...
- Reliance Life Sciences bets big on biosimilarsReliance Life Sciences (RLS), a company promoted by Reliance Industries’ chairman, Mukesh Ambani, is looking at biopharmaceuticals as a hug...
- Stocks to watch: HDFC, Sun Pharma, BHEL, GAIL, ONGC, IFCI, Siemens, Tech Mahindra, BioconCrude oil prices were little changed Thursday after data showed weak demand from the world's top oil user. US crude oil for September deliv...
- Strides Arcolab soars on ending pact with KV PharmaShares of Strides Arcolab rose almost 16 per cent after it ended a license and supply pact with US drug firm KV Pharmaceutical due to negat...
- Glenmark gets nod to sell Zofran generic in USGlenmark Pharmaceuticals has received final approval to market a generic version of GlaxoSmithKline’s popular anti-emetic drug Zofran, that...
- Reliance Life to enter global generic spaceReliance Life Sciences (RLS) is planning to introduce its first generic drug by 2009 in international markets.
- Reliance Life ties up with MPM CapitalReliance Life Sciences (RLS) on Thursday announced that it has entered into a partnership with MPM capital, a global investment firm focuse...
- Reliance LifeScience picks 74% in GeneMedixReliance LifeScience on Wednesday announced the acquisition of a 74% equity stake (1.1 billion shares) in the UK-based biotech firm.
Load More
